Market Cap 636.07M
Revenue (ttm) 40,000.00
Net Income (ttm) -88.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -220,225.00%
Debt to Equity Ratio 0.12
Volume 2,464,700
Avg Vol 4,138,102
Day's Range N/A - N/A
Shares Out 194.52M
Stochastic %K 53%
Beta 0.18
Analysts Strong Sell
Price Target $14.64

Company Profile

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
FatMoneyScience
FatMoneyScience Sep. 15 at 2:04 AM
$ALT Something is certainly going to happen someday. Until then, hold onto your shares and don't get old.
1 · Reply
JackedNicholson
JackedNicholson Sep. 15 at 12:10 AM
$ALT 👀👀👀
4 · Reply
JackedNicholson
JackedNicholson Sep. 14 at 11:34 PM
$ALT Do you guys expect any PR this week?
8 · Reply
Drummerguy
Drummerguy Sep. 14 at 9:47 PM
0 · Reply
JackedNicholson
JackedNicholson Sep. 14 at 9:30 PM
2 · Reply
MySfinktrReeks
MySfinktrReeks Sep. 14 at 8:52 PM
$ALT let's celebrate the 3 penny jump. LOL what a
1 · Reply
Hatrak1
Hatrak1 Sep. 14 at 8:26 PM
$ALT The new look of Goldman Sachs Market Makers ! 🤣
1 · Reply
TradingTherapy
TradingTherapy Sep. 14 at 8:17 PM
1 · Reply
Ascain
Ascain Sep. 14 at 8:11 PM
$ALT Low Volume
1 · Reply
Hewitts
Hewitts Sep. 14 at 8:03 PM
$ALT wonder what they’ll do to save face? Partner up, make an acquisition, or ride the bull off the patent cliff? https://stocktwits.com/news-articles/markets/equity/nvo-stock-why-morgan-stanley-is-bearish-on-novo-nordisk-despite-its-weight-loss-drug-opportunity/cZtXhhNRBGl
3 · Reply
Latest News on ALT
Altimmune reports Q2 EPS (12c), consensus (12c)

2026-08-17T09:49:10.000Z - 4 weeks ago

Altimmune reports Q2 EPS (12c), consensus (12c)


Altimmune Earnings Call Transcript: Q2 2026

Aug 12, 2026, 8:30 AM EDT - 4 weeks ago

Altimmune Earnings Call Transcript: Q2 2026


Altimmune Earnings release: Q2 2026

Aug 12, 2026, 8:30 AM EDT - 4 weeks ago

Altimmune Earnings release: Q2 2026


Altimmune Quarterly report: Q2 2026

Aug 12, 2026, 8:30 AM EDT - 4 weeks ago

Altimmune Quarterly report: Q2 2026


Altimmune Slides: Corporate presentation

Aug 12, 2026, 8:00 AM EDT - 4 weeks ago

Altimmune Slides: Corporate presentation


Altimmune initiates PERFORMA trial

2026-08-03T12:16:41.000Z - 6 weeks ago

Altimmune initiates PERFORMA trial


H.C. Wainwright sees ‘clear Phase 2 win’ for Altimmune

2026-07-28T15:20:26.000Z - 6 weeks ago

H.C. Wainwright sees ‘clear Phase 2 win’ for Altimmune


Altimmune Transcript: Study result

Jul 28, 2026, 8:00 AM EDT - 6 weeks ago

Altimmune Transcript: Study result


Altimmune Press release: Study result

Jul 28, 2026, 8:00 AM EDT - 6 weeks ago

Altimmune Press release: Study result


Altimmune Slides: Study result

Jul 28, 2026, 8:00 AM EDT - 6 weeks ago

Altimmune Slides: Study result


Altimmune announces RECLAIM trial met primary endpoint

2026-07-28T11:26:01.000Z - 6 weeks ago

Altimmune announces RECLAIM trial met primary endpoint


Altimmune initiated with an Outperform at Leerink

2026-06-22T10:46:24.000Z - 2 months ago

Altimmune initiated with an Outperform at Leerink


Altimmune initiated with an Outperform at Leerink

2026-06-22T10:31:03.000Z - 2 months ago

Altimmune initiated with an Outperform at Leerink


Altimmune to Participate in Upcoming Investor Conferences

May 27, 2026, 8:30 AM EDT - 3 months ago

Altimmune to Participate in Upcoming Investor Conferences


Altimmune Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 4 months ago

Altimmune Slides: Corporate presentation


Altimmune price target lowered to $11 from $14 at Citizens

2026-05-14T09:47:49.000Z - 4 months ago

Altimmune price target lowered to $11 from $14 at Citizens


Altimmune Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 4 months ago

Altimmune Earnings Call Transcript: Q1 2026


Altimmune Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 4 months ago

Altimmune Earnings release: Q1 2026


Altimmune Quarterly report: Q1 2026

May 13, 2026, 8:30 AM EDT - 4 months ago

Altimmune Quarterly report: Q1 2026


Altimmune reports Q1 EPS (18c), consensus (25c)

2026-05-13T11:59:47.000Z - 4 months ago

Altimmune reports Q1 EPS (18c), consensus (25c)


Altimmune management to meet with Piper Sandler

2026-04-27T19:56:05.000Z - 4 months ago

Altimmune management to meet with Piper Sandler


Altimmune upgraded to Neutral from Sell at Goldman Sachs

2026-04-24T09:16:13.000Z - 4 months ago

Altimmune upgraded to Neutral from Sell at Goldman Sachs


Altimmune 64.25M share Spot Secondary priced at $3.00

2026-04-23T11:06:36.000Z - 4 months ago

Altimmune 64.25M share Spot Secondary priced at $3.00


Altimmune announces common stock offering, no amount given

2026-04-22T20:28:30.000Z - 4 months ago

Altimmune announces common stock offering, no amount given


Altimmune Transcript: AGM 2026

Apr 16, 2026, 8:30 AM EDT - 5 months ago

Altimmune Transcript: AGM 2026


Altimmune Proxy statement: Proxy Filing

Mar 17, 2026, 8:00 AM EDT - 6 months ago

Altimmune Proxy statement: Proxy Filing


Altimmune Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 9:20 AM EDT - 6 months ago

Altimmune Transcript: Leerink Global Healthcare Conference 2026


Altimmune Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 2:15 PM EDT - 6 months ago

Altimmune Transcript: The Citizens Life Sciences Conference 2026


Altimmune Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 6 months ago

Altimmune Slides: Corporate presentation


Altimmune Proxy statement: Proxy Filing

Mar 6, 2026, 7:00 AM EST - 6 months ago

Altimmune Proxy statement: Proxy Filing


Altimmune Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 6 months ago

Altimmune Earnings Call Transcript: Q4 2025


Altimmune Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 6 months ago

Altimmune Annual report: Q4 2025


Altimmune Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 6 months ago

Altimmune Earnings release: Q4 2025


Altimmune Transcript: Study Result

Dec 19, 2025, 8:00 AM EST - 8 months ago

Altimmune Transcript: Study Result


Altimmune Press release: Study Result

Dec 19, 2025, 8:00 AM EST - 8 months ago

Altimmune Press release: Study Result


Altimmune Slides: Study Result

Dec 19, 2025, 8:00 AM EST - 8 months ago

Altimmune Slides: Study Result


Altimmune Announces CEO Transition and Succession Plan

Dec 1, 2025, 7:30 AM EST - 9 months ago

Altimmune Announces CEO Transition and Succession Plan


Altimmune Registration statement: Registration Filing

Nov 13, 2025, 7:00 AM EST - 10 months ago

Altimmune Registration statement: Registration Filing


Altimmune Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:00 AM EST - 10 months ago

Altimmune Transcript: Stifel 2025 Healthcare Conference


Altimmune Slides: Corporate Presentation

Nov 6, 2025, 4:00 PM EST - 10 months ago

Altimmune Slides: Corporate Presentation


Altimmune Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Altimmune Earnings Call Transcript: Q3 2025


Altimmune Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Altimmune Quarterly report: Q3 2025


Altimmune Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Altimmune Earnings release: Q3 2025


Altimmune Registration statement: Registration Filing

Nov 6, 2025, 7:00 AM EST - 10 months ago

Altimmune Registration statement: Registration Filing


Altimmune to Participate in Two Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 10 months ago

Altimmune to Participate in Two Upcoming Investor Conferences


Altimmune Transcript: Stifel Virtual Cardiometabolic Forum

Sep 30, 2025, 10:30 AM EDT - 11 months ago

Altimmune Transcript: Stifel Virtual Cardiometabolic Forum


Altimmune Transcript: AGM 2025

Sep 25, 2025, 8:30 AM EDT - 11 months ago

Altimmune Transcript: AGM 2025


FatMoneyScience
FatMoneyScience Sep. 15 at 2:04 AM
$ALT Something is certainly going to happen someday. Until then, hold onto your shares and don't get old.
1 · Reply
JackedNicholson
JackedNicholson Sep. 15 at 12:10 AM
$ALT 👀👀👀
4 · Reply
JackedNicholson
JackedNicholson Sep. 14 at 11:34 PM
$ALT Do you guys expect any PR this week?
8 · Reply
Drummerguy
Drummerguy Sep. 14 at 9:47 PM
0 · Reply
JackedNicholson
JackedNicholson Sep. 14 at 9:30 PM
2 · Reply
MySfinktrReeks
MySfinktrReeks Sep. 14 at 8:52 PM
$ALT let's celebrate the 3 penny jump. LOL what a
1 · Reply
Hatrak1
Hatrak1 Sep. 14 at 8:26 PM
$ALT The new look of Goldman Sachs Market Makers ! 🤣
1 · Reply
TradingTherapy
TradingTherapy Sep. 14 at 8:17 PM
1 · Reply
Ascain
Ascain Sep. 14 at 8:11 PM
$ALT Low Volume
1 · Reply
Hewitts
Hewitts Sep. 14 at 8:03 PM
$ALT wonder what they’ll do to save face? Partner up, make an acquisition, or ride the bull off the patent cliff? https://stocktwits.com/news-articles/markets/equity/nvo-stock-why-morgan-stanley-is-bearish-on-novo-nordisk-despite-its-weight-loss-drug-opportunity/cZtXhhNRBGl
3 · Reply
Hatrak1
Hatrak1 Sep. 14 at 8:01 PM
1 · Reply
AchieveNonDillutiveFunds
AchieveNonDillutiveFunds Sep. 14 at 7:58 PM
$ALT maybe!
1 · Reply
TradeSun
TradeSun Sep. 14 at 7:49 PM
$ALT The first PERFORMA site update was already pretty impressive — 9 recruiting sites right out of the gate, including several important and experienced centers. If Altimmune has been batching additional sites over the past ~2 weeks, the next update could be a big one. I wouldn’t be surprised to see 20–30 sites in total. At the upper end, that would already represent ~10% of the planned ~300 sites — very early in the rollout. And remember: trial enrollment and site activation typically gain momentum as the study ramps up. 👇
0 · Reply
LeaperM75
LeaperM75 Sep. 14 at 7:42 PM
1 · Reply
TradeSun
TradeSun Sep. 14 at 7:33 PM
$ALT PERFORMA Phase 3 — what are your expectations for the next update? Currently: 9 sites, 1 country 🇺🇸 When do you expect the next update — and how many sites and countries will we see?
1 · Reply
BuddyBoy6975
BuddyBoy6975 Sep. 14 at 6:55 PM
$ALT Haven’t post an Alt chart in a bit, so…. Daily has been a series of short term rounding bottoms, turning into one big giant one. Absolutely bullish, particularly the recent stretch of higher lows. Gotta love it
1 · Reply
artiebet
artiebet Sep. 14 at 6:45 PM
$ALT 3.50 on deck.
1 · Reply
TradeSun
TradeSun Sep. 14 at 6:36 PM
$ALT I demand an EOD close above $3.33 and a breakout above $3.65 by the end of September. Basta. 😎
1 · Reply
MySfinktrReeks
MySfinktrReeks Sep. 14 at 6:30 PM
$ALT red incoming
1 · Reply
BuddyBoy6975
BuddyBoy6975 Sep. 14 at 6:21 PM
$ALT Hanging tough and incredibly
0 · Reply
LeftyT
LeftyT Sep. 14 at 6:11 PM
$ALT It looks like @PashaGainz has an imitator trying to take his name with a dash added, so I Blocked him.
0 · Reply
ViperV22
ViperV22 Sep. 14 at 6:09 PM
0 · Reply